About this item:

94 Views | 27 Downloads

Author Notes:

Xiaoping P. Hu, xhu@engr.ucr.edu

JL: conceptualization, data curation, formal analysis, methodology, writing – original draft, and writing – review and editing. KH: formal analysis and writing – review and editing. XH and DH: conceptualization, methodology, and writing – review and editing. All authors contributed to the article and approved the submitted version.

Parkinson’s progression markers initiative (PPMI) – a public-private partnership – was funded by the Michael J. Fox Foundation for Parkinson’s Research and funding partners, including (list the full names of all of the PPMI funding partners found at www.ppmi-info.org/about-ppmi/who-we-are/study-sponsors).

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Subject:

Research Funding:

This work was supported by the NIH-NINDS 1K23NS105944-01A1 (DH), NIH-NIA 1U19 AG071754-01 (DH, XH, and JL), the Department of Veteran Affairs 1I01RX002967-01A2 (DH), the Emory American Parkinson’s Disease Association Center for Advanced Research (DH), the Emory Lewy Body Dementia Association Research Center of Excellence (DH), and the Michael J. Fox Foundation for Parkinson’s Research (MJF-10854 and MJFF-010556; DH, XH, and JL).

Keywords:

  • Science & Technology
  • Life Sciences & Biomedicine
  • Neurosciences
  • Neurosciences & Neurology
  • scans without evidence of dopaminergic deficit
  • Parkinson's disease
  • neuromelanin
  • substantia nigra pars compacta
  • free water
  • SUBSTANTIA-NIGRA
  • PARKINSONS-DISEASE
  • LOCUS-COERULEUS
  • IRON CONTENT
  • NEUROMELANIN
  • PROGRESSION
  • BRAIN
  • DEGENERATION
  • VALIDATION
  • DIAGNOSIS

Nigral volumetric and microstructural measures in individuals with scans without evidence of dopaminergic deficit

Tools:

Journal Title:

FRONTIERS IN NEUROSCIENCE

Volume:

Volume 16

Publisher:

, Pages 1048945-1048945

Type of Work:

Article | Final Publisher PDF

Abstract:

Introduction: Striatal dopamine transporter (DAT) imaging using 123I-ioflupane single photon positron emitted computed tomography (SPECT) (DaTScan, GE) identifies 5−20% of newly diagnosed Parkinson’s disease (PD) subjects enrolling in clinical studies to have scans without evidence of dopaminergic deficit (SWEDD). These individuals meet diagnostic criteria for PD, but do not clinically progress as expected, and they are not believed to have neurodegenerative Parkinsonism. Inclusion of SWEDD participants in PD biomarker studies or therapeutic trials may therefore cause them to fail. DaTScan can identify SWEDD individuals, but it is expensive and not widely available; an alternative imaging approach is needed. Here, we evaluate the use of neuromelanin-sensitive, iron-sensitive, and diffusion contrasts in substantia nigra pars compacta (SNpc) to differentiate SWEDD from PD individuals. Methods: Neuromelanin-sensitive, iron-sensitive, and diffusion imaging data for SWEDD, PD, and control subjects were downloaded from the Parkinson’s progression markers initiative (PPMI) database. SNpc volume, SNpc iron (R2), and SNpc free water (FW) were measured for each participant. Results: Significantly smaller SNpc volume was seen in PD as compared to SWEDD (P < 10–3) and control (P < 10–3) subjects. SNpc FW was elevated in the PD group relative to controls (P = 0.017). No group difference was observed in SNpc R2. Conclusion: In conclusion, nigral volume and FW in the SWEDD group were similar to that of controls, while a reduction in nigral volume and increased FW were observed in the PD group relative to SWEDD and control participants. These results suggest that these MRI measures should be explored as a cost-effective alternative to DaTScan for evaluation of the nigrostriatal system.

Copyright information:

© 2022 Langley, Hwang, Hu and Huddleston.

This is an Open Access work distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/).
Export to EndNote